Fast Dissociating Dopamine D2 Antagonists for Schizophrenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic medications for schizophrenia often cause motor side effects and metabolic disorders due to slow dissociation from dopamine D2 receptors and non-selective receptor interactions.
Innovation Solution
Development of novel 6-(piperidin-4-ylamino)pyridazin-3-carbonitrile compounds that act as fast dissociating dopamine 2 receptor antagonists, reducing motor side effects and minimizing interactions with other receptors to lower the risk of metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antipsychotic medications are used to treat schizophrenia, then dopamine D2 receptor blocking effect is achieved, but motor side effects and metabolic disorders occur due to slow dissociation from receptors
Solution Approach 1:
The patent changes the kinetic parameter of receptor interaction by designing compounds with fast dissociation rates from dopamine D2 receptors. This is achieved through specific molecular structure modifications in the pyridazinone core compounds, which alter the binding kinetics to enable rapid dissociation while maintaining therapeutic efficacy, thereby reducing motor side effects like extrapyramidal symptoms
Solution Approach 2:
The invention introduces dynamic characteristics to the drug-receptor interaction by ensuring the compound can rapidly bind and equally rapidly dissociate from the dopamine D2 receptor. This dynamic on-off binding pattern allows the drug to quickly respond to physiological dopamine fluctuations, preventing the sustained blocking that causes motor side effects while maintaining antipsychotic effectiveness
2Reliability
If traditional antipsychotic medications block dopamine D2 receptors, then positive symptoms are treated, but non-selective receptor interactions cause metabolic disorders
Solution Approach 1:
The patent applies local quality by designing the pyridazinone compound to have selective affinity characteristics - while maintaining strong blocking effect at dopamine D2 receptors for therapeutic efficacy, the molecular structure is optimized to minimize interactions with other receptor types. This selective local action at the target receptor reduces off-target effects that cause metabolic disorders such as weight gain and diabetes
3Duration of action of stationary object
If slow dissociating compounds are used, then sustained receptor occupancy is achieved, but physiological dopamine transmission is impaired
Solution Approach 1:
The invention implements periodic action through rapid cycling of binding and dissociation events. The compound binds to dopamine D2 receptors and quickly dissociates, creating a periodic pattern of occupancy that allows physiological dopamine to periodically displace and rebind. This rhythmic interaction maintains sustained therapeutic effect while preserving the natural dopamine transmission cycles necessary for normal motor function
Data Source
AI summary
The present invention relates to 6-(piperidin-4-ylamino)pyridazin-3-carbonitriles of the general formula (I);or a pharmaceutically acceptable salt thereof, or a stereoisomeric form, that are fast dissociating dopamine 2 receptor antagonists, as well as processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.